Skip to Content

ASCO20: How does early treatment influence the sequence of the following treatment if the disease progresses?

In this MEDtalk Eric J. Small, MD and principal investigator of the SPARTAN study, explains the clinical benefits from early treatment of patients with nonmetastatic castration-resistant prostate cancer

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top